Panel Discussion: Why Are Big Pharma Betting on Targeted Radiopharmaceuticals?
5:30 pm - Wednesday 2nd December 2026
- Exploring the scientific, clinical and commercial factors driving increasing investment into targeted radiopharmaceuticals from large pharmaceutical companies
- Comparing the evolution of the radiopharmaceutical landscape with the rapid growth of antibody-drug conjugates and identifying the key lessons that can be applied across modalities
- Debating whether radiopharmaceuticals are approaching a similar inflection point to ADCs and what challenges still need to be overcome to unlock broader adoption
